Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 8, 2004, Pages 524-533

  Asavaroengchai, W ^a   Kotera, Y ^a   Koike, N ^a   Pilon Thomas, S ^a,b   Mule J J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antitumor immune response; Bone marrow transplantation; Lymphoid reconstitution; Tumor lysate pulsed dendritic cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW CELL; BREAST CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MODEL; DONOR; EFFECTOR CELL; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNE RESPONSE; IMMUNIZATION; KNOCKOUT MOUSE; LUNG METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFER; LYMPHOCYTOPENIA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PURIFICATION; RECIPIENT; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENES, MHC CLASS I; IMMUNOPHENOTYPING; INTERFERON TYPE II; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES; VACCINATION;

EID: 3543125930     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.04.003     Document Type: Article

References (57)

1. Mehta J. Powles R. Treleaven J. et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy Bone Marrow Transplant. 19 1997 709-719
2. Martin T.G. Gajewski J.L. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults Hematol Oncol Clin North Am. 15 2001 97-120
3. Eapen M. Ramsay N.K. Mertens A.C. Robison L.L. DeFor T. Davies S.M. Late outcomes after allogeneic bone marrow transplant for aplastic anaemia Br J Haematol. 111 2000 754-760
4. Choi S.J. Lee K.H. Kim S. et al. Prognosis value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study Bone Marrow Transplant. 26 2000 327-332
5. Zang D.Y. Deeg H.J. Gooley T. et al. Treatment of chronic myelomonocytic leukemia by allogeneic marrow transplantation Br J Haematol. 110 2000 217-222
6. Osarogiagbon R.U. Defor T.E. Weisdorf M.A. Erice A. Weisdorf D.J. CMV antigenemia following bone marrow transplantation: risks factors and outcomes Biol Blood Marrow Transplant. 6 2000 280-288
7. Fleming D.R. Doukas M.A. Jennings D.C. Davey D.D. Diagnostic and clinical implications of lineage fidelity in acute leukemia patients undergoing allogeneic stem cell transplantation Leuk Lymphoma 36 2000 309-313
8. Cabrera R. Diaz-Espada F. Barrios Y. et al. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma Bone Marrow Transplant. 25 2000 1105-1108
9. Labadie J. van Tol M.J. Dijkstra N.H. et al. Transfer of specific immunity from donor to recipient of an allogeneic bone marrow graft: evidence for donor origin of the antibody producing cells Br J Haematol. 82 1992 437-444
10. Lum L.G. Seigneuret M.C. Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients J Clin Immunol. 6 1986 389-396
11. Saxon A. Mitsuyasu R. Stevens R. Champlin R.E. Kimata H. Gale R.P. Designed transfer of specific immune responses with bone marrow transplantation J Clin Invest. 78 1986 959-967
12. Kwak L.W. Taub D.D. Duffey P.L. et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor Lancet 345 1995 1016-1020
13. Hornung R.L. Longo D.L. Bowersox O.C. Kwak L.W. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor J Natl Cancer Inst. 87 1995 1289-1296
14. Kwak L.W. Campbell M.J. Zelenetz A.D. Levy R. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy Blood 78 1991 2768 -2772
15. Kwak L.W. Pennington R. Longo D.L. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts Blood 87 1996 3053-3060
16. Fontaine P. Roy-Proulx G. Knafo L. Baron C. Roy D.C. Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease Nat Med. 7 2001 789-794
17. Zeis M. Steinmann J. Petrela E. Hartung G. Schmitz N. Uharek L. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice Bone Marrow Transplant. 27 2001 279-285
18. Morecki S. Yacovlev E. Gelfand Y. Uzi I. Slavin S. Cell therapy with preimmunized effector cells mismatched for minor histocompatibility antigens in the treatment of a murine mammary carcinoma J Immunother. 24 2001 114-121
19. Feuerer M. Beckhove P. Bai L. et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow Nat Med. 7 2001 452-458
20. Peng L. Kjaergaard J. Plautz G.E. Weng D.E. Shu S. Cohen P.A. Helper-independent, L-selectin low CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression J Immunol. 165 2000 5738-5749
21. To W.C. Seeley B.M. Barthel S.W. Shu S. Therapeutic efficacy of Th1 and Th2 L-selectin-CD4+ tumor-reactive T cells Laryngoscope 110 2000 1648-1654
22. Zeis M. Uharek L. Glass B. et al. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation Exp Hematol. 26 1998 1068-1073
23. Cui Y. Kelleher E. Straley E. et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells Nat Med. 9 2003 952-958
24. Geiger J. Hutchinson R. Hohenkirk L. McKenna E. Chang A. Mulé J.J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells Lancet 356 2000 1163-1165
25. Shimizu K. Fields R. Giedlin M. Mulé J.J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines Proc Natl Acad Sci U S A 96 1999 2268-2273
26. Fields R.C. Shimizu K. Mulé J.J. Murine dendritic cells pulsed with whole lysates mediate potent antitumor immune responses in vitro and in vivo Proc Natl Acad Sci U S A 95 1998 9482-9487
27. Herr W. Ranieri E. Olson W. Zarour H. Gesualdo L. Storkus W.J. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses Blood 96 2000 1857-1864
28. Kobayashi T. Shinohara H. Toyoda M. Iwamoto S. Tanigawa N. Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case Surg Today 31 2001 513-516
29. Nestle F.O. Alijagic S. Gilliet M. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med. 4 1998 328-332
30. Lambert L.A. Gibson G.R. Maloney M. Barth Jr. R.J. Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens J Immunother. 24 2001 232-236
31. Indrova M. Bubenik J. Simova J. et al. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide Int J Mol Med. 7 2001 97-100
32. DeMatos P. Abdel-Wahab Z. Vervaert C. Hester D. Seigler H. Pulsing of dendritic cells with lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice J Surg Oncol. 68 1998 79-91
33. Asavaroengchai W. Kotera Y. Mulé J.J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery Proc Natl Acad Sci U S A 99 2002 931-936
34. Mackall C.L. Hakim F.T. Gress R.E. T-cell regeneration: all repertoires are not created equal Immunol Today 18 1997 245-251
35. Lum L.G. The kinetics of immune reconstitution after human marrow transplantation Blood 69 1987 369-380
36. Mackall C.L. Granger L. Sheard M.A. Cepeda R. Gress R.E. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny Blood 82 1993 2585-2594
37. Bell E.B. Sparshott S.M. Drayson M.T. Hunt S.V. The origin of T cells in permanently reconstituted old athymic nude rats. Analysis using chromosome or allotype markers Immunology 68 1989 547-556
38. Rocha B.B. Population kinetics of precursors of IL 2-producing peripheral T lymphocytes: evidence for short life expectancy, continuous renewal, and post-thymic expansion J Immunol. 139 1987 365-372
39. Rocha B. Dautigny N. Pereira P. Peripheral T lymphocytes: Expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo Eur J Immunol. 19 1989 905-911
40. Drayson M.T. Sparshott S.M. Bell E.B. Fidelity of the repertoire in T cell reconstituted athymic nude rats. Preservation of a deficit in alloresponsiveness over one year J Exp Med. 170 1989 691-702
41. Margaretten N.C. Witschi H. Effects of hyperoxia on growth characteristics of metastatic murine tumors in the lung Cancer Res. 48 1988 2779-2783
42. Kim K.J. Kanellopoulos-Langevin C. Merwin R.M. Sachs D.H. Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties J Immunol. 122 1979 549-554
43. Ernst B. Lee D.S. Chang J.M. Sprent J. Surh C.D. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery Immunity 11 1999 173-181
44. Ge Q. Rao V.P. Cho B.K. Eisen H.N. Chen J. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/MHC epitopes and strength of their interaction with T cell receptors Proc Natl Acad Sci U S A 98 2001 1728-1733
45. La Gruta N.L. Driel I.R. Gleeson P.A. Peripheral T cell expansion in lymphopenic mice results in a restricted T cell repertoire Eur J Immunol. 30 2000 3380-3386
46. Amrani A. Serra P. Yamanouchi J. et al. Expansion of the antigenic repertoire of a single T cell receptor upon T cell activation J Immunol. 167 2001 655-666
47. Surh C.D. Ernst B. Lee D.S. Dummer W. LeRoy E. Role of self-major histocompatibility complex/peptide ligands in selection and maintenance of a diverse T cell repertoire Immunol Res. 21 2000 331-339
48. Rocha B. Dautigny N. Pereira P. Peripheral T lymphocytes: expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo Eur J Immunol. 19 1989 905-911
49. Zhang Z.X. Young K. Zhang L. CD3+CD4-CD8- alphabeta-TCR+ T cell as immune regulatory cell J Mol Med. 79 2001 419-427
50. Abraham V.S. Sachs D.H. Sykes M. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population J Immunol. 148 1992 3746-3752
51. Palathumpat V. Dejbakhsh-Jones S. Holm B. Wang H. Liang O. Strober S. Studies of CD4- CD8- alpha beta bone marrow T cells with suppressor activity J Immunol. 148 1992 373-380
52. Palathumpat V. Dejbakhsh-Jones S. Holm B. Strober S. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease J Immunol. 149 1992 808-817
53. Zhang Z.X. Yang L. Young K.J. DuTemple B. Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression Nat Med. 6 2000 782-789
54. Yamagiwa S. Sugahara S. Shimizu T. et al. The primary site of CD4- 8- B220+ alphabeta T cells in lpr mice: the appendix in normal mice J Immunol. 160 1998 2665-2674
55. Ohteki T. Seki S. Abo T. Kumagai K. Liver is a possible site for the proliferation of abnormal CD3+4-8- double-negative lymphocytes in autoimmune MRL-lpr/lpr mice J Exp Med. 172 1990 7-12
56. Borrello I. Sotomayor E.M. Rattis F.M. Cooke S.K. Gu L. Levitsky H.I. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines Blood 95 2000 3011-3019
57. Pawlowska A.B. Hashino S. McKenna H. Weigel B.J. Taylor P.A. Blazar B.R. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice Blood 97 2001 1474-1482